Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
185 hedge funds and large institutions have $2.96B invested in Amicus Therapeutics in 2017 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 77 increasing their positions, 56 reducing their positions, and 26 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 56
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
18% more call options, than puts
Call options by funds: $95.2M | Put options by funds: $80.6M
0% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 26
1% less funds holding
Funds holding: 186 → 185 (-1)
1% less capital invested
Capital invested by funds: $2.99B → $2.96B (-$29.3M)
10.45% less ownership
Funds ownership: 120.56% → 110.11% (-10%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$76.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$24.6M |
| 3 |
Millennium Management
New York
|
+$18.1M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$15.7M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$15.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$31.6M |
| 2 |
D.E. Shaw & Co
New York
|
-$28.2M |
| 3 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$19.4M |
| 4 |
Morgan Stanley
New York
|
-$19M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$18.3M |
FOLD Hedge Fund Activity: Q4 2017 in Review
185 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q4 2017, worth a combined $2.96B — down 0.98% from $2.99B a quarter earlier.
Fund positioning in FOLD was balanced in Q4 2017: 26 funds opened new positions, 26 closed out, 77 added to existing stakes and 56 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $76.6M. The largest seller was Farallon Capital Management, cutting an estimated $31.6M.
- 185 institutional investors held Amicus Therapeutics (FOLD) as of Q4 2017, down from 186 in Q3 2017.
- Funds reported $2.96B of Amicus Therapeutics stock for Q4 2017, down 0.98% quarter-over-quarter.
- 26 funds opened new Amicus Therapeutics positions in Q4 2017 and 26 closed out, a net change of 0 holders.
- The largest Amicus Therapeutics buyer in Q4 2017 was OrbiMed, an estimated $76.6M added.
- The largest Amicus Therapeutics seller in Q4 2017 was Farallon Capital Management, an estimated $31.6M sold.
Based on aggregated 13F filings for Q4 2017.